Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The AURA Study.

Trial Profile

Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The AURA Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2017

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms AURA
  • Sponsors AstraZeneca; Takeda
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Sep 2013 Pooled analysis presented at the 23rd Annual Congress of the European Respiratory Society.
    • 07 May 2012 Additional company (Takeda Global Research and Development Center) added in association as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top